SN-38

For research use only. Not for use in humans.

目录号:S4908

SN-38 Chemical Structure

CAS No. 86639-52-3

SN-38 是CPT-11的一种活性代谢物,抑制DNA topoisomerase I,DNA合成,并造成频繁的DNA单链断裂。SN-38 可诱导自噬。

规格 价格 库存 购买数量  
RMB 742.35 现货
RMB 3013.44 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的SN-38发表文献27篇:

产品安全说明书

ADC Cytotoxin抑制剂选择性比较

生物活性

产品描述 SN-38 是CPT-11的一种活性代谢物,抑制DNA topoisomerase I,DNA合成,并造成频繁的DNA单链断裂。SN-38 可诱导自噬。
靶点
Topo I [1]
(Cell-free assay)
体外研究

SN-38是伊立替康盐酸盐(CPT-11)的生物活性代谢物。SN-38引起DNA拓扑异构酶I的抑制最强,其次是CPT,然后是CPT-11。 CPT-11剂量依赖性地转移宽松的DNA在切口的DNA的方向上的位置,但SN-38和CPT对宽松的DNA的位置没有影响。SN-38的剂量依赖性和时间依赖性地抑制DNA的合成。 SN-38的各自的IC50值,在DNA合成是0.077微米。SN-38的细胞RNA合成的抑制作用小于对DNA合成和它不抑制蛋白质的合成。 SN-38对P388细胞造成频繁的DNA单链断裂。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human PC6 cells MnLnVJJwdGmoZYLheIlwdiCjc4PhfS=> NXT2NpQ6PiCmYYnz MkfvRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{[gZ4VtdHNiY3HydplqdmdicGLDJIFnfGW{IE[g[IF6eyxiSVO1NF0xNjR|IH7N NXXmVFFUOTl{NUS4OFM>
human HCT116 cells NWjBO4Q6WHKxbHnm[ZJifGmxbjDhd5NigQ>? NETh[4E{KGSjeYO= NU\rc|ZWSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgN{Bl[Xm|LDDJR|UxRTBwNUWgcm0> NYLHSIc{OTl{NUS4OFM>
human PC3 cells M{fJNmN6fG:2b4jpZ:Kh[XO|YYm= Mn\CO|IhcA>? NGm5RmFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh\XiycnXzd4lv\yCjbIDoZVVj\XSjMzDpcpRm\3KrbjDhd5Nme3OnZDDhd{Bk\WyuIIP1dpZqfmGuIHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFnDOVA:Oi54IH7N M3H2[lIzQTV7MkS2
human A549 cells NVrMSIpKS3m2b4TvfIlkyqCjc4PhfS=> M3v4WFMh\GG7cx?= M1XkRmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhOyCmYYnzJIJ6KFOUQjDhd5NigSxiSVO1NF0zNjd{IH7N NY\IeopyOjR3Mkm4O|A>
human QG56 cells MWrQdo9tcW[ncnH0bY9vKGG|c3H5 M1;aN|Mh\GG7cx?= MWLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFGJNU[gZ4VtdHNiYX\0[ZIhOyCmYYnzMEBKSzVyPUKuPEBvVQ>? Mn7oNVkzPTR6NEO=
human NCI-H460 cells MX;Qdo9tcW[ncnH0bY9vKGG|c3H5 MX2zJIRigXN? MW\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IOFYxKGOnbHzzJIFnfGW{IEOg[IF6eyxiSVO1NF0{NjNibl2= MXOxPVI2PDh2Mx?=
human DU145 cells NFTUUYpRem:uaX\ldoF1cW:wIHHzd4F6 NXXRdmRHQTZiaB?= NIHIU2ZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTVNVQ2KGOnbHzzJIFnfGW{IEm2JIhzeyxiSVO1NF01KG6P Ml\2NVgzPzZzNEG=
human breast cancer cell line (SK-BR-3) M3e0TmN6fG:2b4jpZ:Kh[XO|YYm= NXzpW5lYUW5iVnn0do8h[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4h[nKnYYP0JINidmOncjDj[YxtKGyrbnWgLHNMNUKULUOpMEBKSzVyPUSgcm0> NU\IS3hzOTF|M{S1Olk>
human KB3-1 cells NH\icYVEgXSxdH;4bYPDqGG|c3H5 NUDqU5FjPCCmYYnz NH7BXWlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMSjNvMTDj[YxteyCjZoTldkA1KGSjeYOgZpkhVVSWIH3leIhw\CxiSVO1NF01KG6P MXexPVMxOzNyNh?=
human HCT116 cells M33hNmN6fG:2b4jpZ:Kh[XO|YYm= NFvabG04OiCq M2H5[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTygTWM2OD12LkK4JI5O MkDYNlU5OzV|NUm=
MDA-MB-435 S human breast cancer cells NV\qe29sTnWwY4Tpc44h[XO|YYm= MoHPTY5pcWKrdHnvckBi\2GrboP0JG1FSS2PQj20N|UhWyCqdX3hckBjemWjc4SgZ4Fv[2W{IHPlcIx{KGmwIITo[UBi[nOnbnPlJI9nKGGuYoXtbY4tKEmFNUC9OUBvVQ>? MWexNVA2OjhyMh?=
human HT-29 cells M4nFNGN6fG:2b4jpZ:Kh[XO|YYm= MnLvR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTHQuOjliY3XscJMtKEmFNUC9OU46KG6P M3v5NVIyPDdyOE[0
human lung cancer cell line (H128) M2Hy[2N6fG:2b4jpZ:Kh[XO|YYm= NUfnVJNpUW5iVnn0do8h[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hdHWwZzDjZY5k\XJiY3XscEBtcW6nIDjINVI5MSxiSVO1NF03KG6P NWrl[VBCOTF|M{S1Olk>
human MIA PaCa cells MlP5VJJwdGmoZYLheIlwdiCjc4PhfS=> M3LBZmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVnBJHBiS2FiY3XscJMh[W[2ZYKgPVYhcHK|LDDJR|UxRTZibl2= NWX6b3Z2OTh{N{[xOFE>
human HCT116 colon cancer cell line NU\oOY9lTnWwY4Tpc44h[XO|YYm= NHjjVWdKdmirYnn0c5J6KGOxbnPlcpRz[XSrb36gZYdicW6|dDDoeY1idiCKQ2SxNVYh[2:ub36gZ4Fv[2W{IHPlcIwhdGmwZTygTWM2OD15IH7N NV[x[HM5OTV6MEi0OVY>
human stomach cancer cell line (MKN45) MlKzR5l1d3SxeHnjxsBie3OjeR?= MmfTTY4hXmm2cn:gZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gd5RwdWGlaDDjZY5k\XJiY3XscEBtcW6nIDjNT241PSluIFnDOVA:QCCwTR?= M{PWT|EyOzN2NU[5
human A2780 cells MkKwR5l1d3SxeHnjxsBie3OjeR?= M4DmfFczKGh? MXTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{BwfmW{ZYjwdoV{e2mwZzDhcJBp[TWkZYThN{BqdnSnZ4LpckBie3Onc4Pl[EBieyClZXzsJJN2en[rdnHsJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;OTDuUS=> MXqyNlk2QTJ2Nh?=
human ovarian cancer cell line (SK-OV-3) M{PHdGN6fG:2b4jpZ:Kh[XO|YYm= NGC2SmZKdiCYaYTyc{BkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBwfmG{aXHuJINidmOncjDj[YxtKGyrbnWgLHNMNU:YLUOpMEBKSzVyPUGxJI5O NHHlbIEyOTN|NEW2PS=>
human DU145 prostate cell line NYrQS4d2WHKxbHnm[ZJifGmxbjDhd5NigQ>? MWnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESXMUS1JJBzd3O2YYTlJINmdGxibHnu[UwhUUN3ME2xN{BvVQ>? M1S0OFExPDl6MkG2
human colon cancer cell line (WiDr) NEO4[pdEgXSxdH;4bYPDqGG|c3H5 MU\JckBXcXS{bzDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDjc4xwdiClYX7j[ZIh[2WubDDsbY5mKCiZaVTyLUwhUUN3ME2xOEBvVQ>? MnzrNVE{OzR3Nkm=
human lung cancer cell line (A549) MXzDfZRwfG:6aXRCpIF{e2G7 M1XG[mlvKF[rdILvJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIx2dmdiY3HuZ4VzKGOnbHygcIlv\SBqQUW0PUk> NX3pUYd3OTF|M{S1Olk>
human tumor HL60 cell-line Mn3YSpVv[3Srb36gZZN{[Xl? NI\IbXE{KGSjeYO= NGr2WGxKdi24aYTyc{BqdmirYnn0c5J6KGOxbnPlcpRz[XSrb36g[o9zKGi3bXHuJJR2dW:{IFjMOlAh[2WubD3sbY5mKHejczDk[ZRmem2rbnXkJJV{cW6pIGPSRkBie3OjeTDh[pRmeiB|IHThfZMhd2ZiaX7jeYJifGmxbjygTWM2OD1zOTDuUS=> MVuxOVkyOzl7Nh?=
PC-3 carcinoma cell line NHXhelNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHH2dXVEd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSg[5Jwf3SqIH;mJIh2dWGwIIDyc5N1[XSnIGDDMVMh[2G{Y3nuc41iKGOnbHygcIlv\SxiSVO1NF0{PS54IH7N Ml7aNVU1PTR{M{C=
human KBV1 cells MWTDfZRwfG:6aXRCpIF{e2G7 MoTPOEBl[Xm| MlL0R5l1d3SxeHnjbZR6KGGpYXnud5QhVUSUMTDveoVz\XiycnXzd4lv\yCqdX3hckBMSlZzIHPlcIx{KGGodHXyJFQh\GG7czDifUBOXFRibXX0bI9lNCCLQ{WwQVQ3KG6P MlvpNVk{ODN|ME[=
human A549 cells NGrSNZVEgXSxdH;4bYPDqGG|c3H5 MlyyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{whUUN3ME20O{BvVQ>? Ml;wNlE1PzB6NkS=
NSCLC-H460 NGLyU5dEgXSxdH;4bYPDqGG|c3H5 Mmf3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gco9vNXOvYXzsMYNmdGxibIXu[{Bk[XKlaX7vcYEh[2WubDDsbY5mKEh2NkCgLG5US0yFLVi0OlAqNCCLQ{WwQVgxKG6P M3X6fVEyPTZ|OUK1
MDA-MB-435 S human breast cancer cells MorGSpVv[3Srb36gZZN{[Xl? M1vudGlvcGmkaYTpc44h[WejaX7zeEBOTEFvTVKtOFM2KFNiaIXtZY4h[nKnYYP0JINidmOncjDj[YxteyCrbjD0bIUheHKnc3XuZ4Uhd2ZiM{CgcYcwdUxiSGPBMEBKSzVyPUWwJI5O M2D0SFEyODV{OECy
human H460 cell MnyyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXXJcohq[mm2aX;uJI9nKGi3bXHuJGg1PjBiY3XscEBoem:5dHisJGlEPTB;OECgcm0> MoD5NVY6OTN5ME[=
human MDA-MB-231 cells M37PTGN6fG:2b4jpZ:Kh[XO|YYm= MlnCR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczygTWM2OD1zN{[gcm0> MUOyOFUzQTh5MB?=
human KBH5.0 cells M13aZmN6fG:2b4jpZ:Kh[XO|YYm= NH7MeJo1KGSjeYO= NID3dGpEgXSxdH;4bYNqfHliYXfhbY5{fCCEQ2LQJI93\XKneIDy[ZN{cW6pIHj1cYFvKEuESEWuNEBk\WyuczDh[pRmeiB2IHThfZMh[nliTWTUJI1mfGixZDygTWM2OD1yLkOg{txO MoPlNVk{ODN|ME[=
human MCF-7 breast cell line MUTQdo9tcW[ncnH0bY9vKGG|c3H5 NH73boRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSk04KGK{ZXHzeEBk\WyuIHzpcoUtKEmFNUC9NE4{PyEQvF2= MWqxNFQ6QDJzNh?=
human SKOV-3 ovarian cell line MkWyVJJwdGmoZYLheIlwdiCjc4PhfS=> NHzXc4NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLU3YuOyCxdnHybYFvKGOnbHygcIlv\SxiSVO1NF0xNjd{IN88US=> NY[3bIZNOTB2OUiyNVY>
human Bel-7402 liver cancer cell line NH3VcnFHfW6ldHnvckBie3OjeR?= MYXJcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCCqdX3hckBD\WxvN{SwNkBtcX[ncjDjZY5k\XJiY3XscEBtcW6nLDDJR|UxRTNwMUmg{txO MljsNVU5ODh2NU[=
HEK293 cells NXLxU5UzS3m2b4TvfIlkyqCjc4PhfS=> Mnn4O|IhcA>? MYfJcpRzcW6|aXOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhUEWNMkmzJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5 NHfjVVczPTJ5MkC1OS=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-Chk1 / Chk1 / Topo I ; 

PubMed: 18509065     


Log-phase Ovcar-5 cells were treated for 24 h with diluent (0.1% DMSO, lanes 1 and 6), gemcitabine at 12.5, 25, 50 or 100 nM (lanes 2-5, respectively), or SN-38 at 2.5, 5, 10, 20 and 40 nM in the absence (lanes 7-11) or presence (lanes 12-17) of 50 nM gemcitabine. At the end of the incubation, whole cell lysates were prepared, subjected to SDS-PAGE, transferred to nitrocellulose, and probed with reagents that recognize phospho-Ser345-Chk1, total Chk1, topo I or, as control, β-actin. Because of the limited number of lanes on our electrophoresis apparatus, lanes 1-5 and 6-17 represent two different membranes from the same experiment that were probed simultaneously.

18509065
Growth inhibition assay
Cell viability; 

PubMed: 25759163     


(A) Drug sensitivity towards SN‐38 and oxaliplatin for the parental and drug resistant cell lines. Cells were exposed to a range of drug concentrations for 48 h and cell viability was assessed by an endpoint MTT assay. Results of representative experiments are shown. Green (triangle) is the parental cell line, blue (diamond) the SN‐38 resistant cell line, and red (square) the oxaliplatin resistant cell line.

25759163
体内研究 口服给药后,SN-38的最高浓度出现在1小时后,并且未结合的SN-38内酯在小鼠血浆在1000纳克/毫升时百分比是3.4 +/- 0.67%,而在100纳克/毫升的未结合的百分比是1.18 +/- 0.14%。在含人类神经母细胞瘤的裸鼠中SN-38内酯的AUC大于在非肿瘤息动物的量。

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

拓扑异构酶I检测:

一个单位(本研究的条件下,使0.5微克SV40 DNA完全松弛的最小量)拓扑异构酶I, 0.5微升的测试化合物,和0.5μg SV40的DNA按顺序加入反应缓冲液中,它是由25毫摩尔Tris -盐酸(pH值7.5),50 mM的KCl, 5 mM的氯化镁,0.25毫摩尔EDTA二钠盐,0.25 mM二硫苏糖醇,15 μg/毫升牛血清白蛋白和5 %的甘油。然后,将反应混合物(50 μL)在37 ℃温育10分钟,并将该反应通过7.5 μL 溶液在37 ℃温育30分钟终止, 1%十二烷基硫酸钠, 20 mM的EDTA二钠盐,和0.5 mg/mL 蛋白酶K。 样品和5 μL 的上样缓冲液混合,上样缓冲液包含10 mM磷酸氢二钠,31.3%蔗糖,0.3%溴酚蓝。松弛(Ir形式)的DNA从超螺旋(形式I)中分离,带切口的( II型)的DNA通过电泳在0.8%琼脂糖凝胶分离,电泳是在在2 μg/mL chloroquine, 10 mM EDTA, 30 mM 磷酸氢二钠存在下在50毫安和20 V条件下进行17小时。电泳后,将凝胶用0.05%溴化乙锭染色并用UV光(302纳米)拍摄。 DNA量是用密度计进行定量。
细胞实验:[3]
- 合并
  • Cell lines: A-172, U-87和LA-567
  • Concentrations: 0 -1000 nM
  • Incubation Time: 48 小时
  • Method: MTT 检测
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 21 mg/mL (53.51 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 392.4
化学式

C22H20N2O5

CAS号 86639-52-3
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03964727 Suspended Biological: IMMU-132 Metastatic Non-Small Cell Lung Carcinoma|Head and Neck Squamous Cell Carcinoma|Endometrial Cancer Immunomedics Inc. August 6 2019 Phase 2
NCT03995706 Recruiting Drug: Sacituzumab Govitecan Glioblastoma The University of Texas Health Science Center at San Antonio|Immunomedics Inc. July 17 2019 Early Phase 1
NCT03245450 Recruiting Drug: Eribulin mesilate|Drug: Irinotecan hydrochloride Refractory or Recurrent Solid Tumors|Rhabdomyosarcoma|Non-Rhabdomyosarcoma Soft Tissue Sarcoma|Ewing Sarcoma Eisai Inc. February 22 2018 Phase 1|Phase 2
NCT03221400 Recruiting Drug: PEN-866 Sodium|Drug: fluorouracil|Drug: Folinic acid Carcinoma|Endometrial Adenocarcinoma|Neoplasms|Squamous Cell Carcinoma of the Anus|Adenocarcinoma of the Pancreas|Advanced Cancer|Solid Tumor|Solid Carcinoma|Squamous Cell Carcinoma of the Cervix|Squamous Cell Carcinoma|Squamous Cell Carcinoma of the Vulva|Squamous Cell Carcinoma of the Penis|Gastric Cancer|Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Small-cell Lung Cancer|Small Cell Lung Carcinoma|Pancreatic Ductal Adenocarcinoma|Pancreatic Adenocarcinoma Tarveda Therapeutics August 29 2017 Phase 1|Phase 2
NCT03096340 Unknown status Drug: IT-141 Cancer|Neoplasms|Tumors|Refractory Solid Tumors|Recurrent Solid Tumors Intezyne Technologies Inc. March 23 2017 Phase 1
NCT02785068 Withdrawn Drug: MM-151|Drug: nal-IRI|Drug: Leucovorin|Drug: 5-FU Colorectal Cancer Merrimack Pharmaceuticals July 2016 Phase 1|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
Tags: 购买SN-38 | SN-38供应商 | 采购SN-38 | SN-38价格 | SN-38生产 | 订购SN-38 | SN-38代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID